Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

PaperCitations, authors & open-access status

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 2,547 citations, 2018 year and closed oa status.

2,547
Citations
2018
Year
closed
OA Status

Related on ScholarIQ

Benjamin M. Parsons
Author
The Lancet Oncology
Journal
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Cancer Immunotherapy and Biomarkers
Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Topic
470M+ articles · free account